Skip to content

Loeb & Loeb Launches FDA Regulatory and Compliance Practice with Addition of Partner Scott Liebman

NEW YORK – Loeb & Loeb LLP announced today that Scott S. Liebman has joined the firm’s New York and Washington, DC offices as a partner. Liebman will lead the firm’s new FDA Regulatory and Compliance practice, which will serve health and life sciences clients engaged in the manufacture, marketing or distribution of FDA-regulated products. Most recently, Liebman was a principal in the New York office of Porzio Bromberg & Newman P.C., where he also served as vice president of the firm’s subsidiary, Porzio Life Sciences LLC.

“Launching a FDA Regulatory and Compliance practice is a natural progression for Loeb, building upon our interdisciplinary strengths and focusing on strategic growth that is complementary to many of our core offerings,” said Michael D. Beck, chairman of Loeb & Loeb. “Scott’s significant experience counseling pharma and medical device companies on complex regulatory compliance and commercialization matters bridges the sophisticated transactional, IP and litigation services that the firm has historically offered to clients in this space.”

Liebman’s practice focuses on FDA and life sciences regulation. He specializes in the performance of audits, gap analyses and risk assessments for leaders in the life sciences industry. He also has extensive experience crafting and implementing comprehensive federal and state law compliance programs for pharmaceutical, medical device and biotechnology companies. Liebman offers niche guidance related to pharmaceutical regulation like the Food, Drug and Cosmetic Act, the Prescription Drug Marketing Act, the Anti-kickback Statute, the False Claims Act, the Patient Protection and Affordable Care Act, and the Food & Drug Administration Modernization Act of 1997. Over his career, he has worked directly with more than one third of the Fortune 500 companies in the pharmaceuticals and medical products and equipment categories, and half of the FDA’s top 50 sponsors of clinical trials by volume.

Loeb & Loeb’s new FDA Regulatory and Compliance Practice, anchored by Liebman, will comprise an interdisciplinary team of regulatory, corporate, patent and litigation attorneys, who will advise clients on the full spectrum of legal and business issues related to the manufacturing and distribution, as well as marketing and promotion of FDA-regulated products. Focusing in the health and life sciences industries, including pharmaceuticals, biologics, medical devices, wellness products, dietary supplements and organics, the practice will counsel clients on regulatory issues and compliance-related matters; advise on laws and regulations related to product advertising and labeling; counsel on FDA exclusivity policies and related Hatch-Waxman issues; and provide representation in licensing transactions and regulatory enforcement actions.

“I am thrilled to be joining Loeb & Loeb and see significant opportunity to apply my specialized regulatory expertise in many different areas at the firm,” said Liebman. “Loeb & Loeb has an excellent national reputation and I look forward to working with this sophisticated team.”

Admitted to the New York and New Jersey bars, Liebman earned his J.D. from Seton Hall University School of Law, where he was a member of the Seton Hall Journal of Sports & Entertainment Law. He received a B.A., with high honors, from Lehigh University.

About Loeb & Loeb LLP
Loeb & Loeb is a multiservice law firm with more than 300 attorneys focusing on select practice areas, rather than endeavoring to be all things to all clients. The firm is recognized as a leading law firm in the areas of capital markets; consumer protection defense; corporate; media and entertainment; intellectual property; litigation; real estate; technology; and tax and wealth services. Loeb & Loeb has offices in Los Angeles, New York, Chicago, Nashville, Washington, DC, and Beijing, as well as an affiliate office in Hong Kong.